Intracellular delivery of doxorubicin encapsulated in novel pH-responsive chitosan/heparin nanocapsules
Received 5 September 2012
Accepted for publication 22 October 2012
Published 11 January 2013 Volume 2013:8(1) Pages 267—273
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 2
Midhun B Thomas,1,* Krishna Radhakrishnan,1,* Divya P Gnanadhas,2,* Dipshikha Chakravortty,2 Ashok M Raichur1,3
1Department of Materials Engineering, 2Department of Microbiology and Cell Biology, Indian Institute of Science, Bangalore, India; 3Department of Applied Chemistry, University of Johannesburg, Doornfontein, South Africa
*These authors contributed equally to this work
Abstract: A novel polyelectrolyte nanocapsule system composed of biopolymers, chitosan and heparin has been fabricated by the layer-by-layer technique on silica nanoparticles followed by dissolution of the silica core. The nanocapsules were of the size range 200 ± 20 nm and loaded with the positively charged anticancer drug doxorubicin with an efficiency of 89%. The loading of the drug into the capsule happens by virtue of the pH-responsive property of the capsule wall, which is determined by the pKa of the polyelectrolytes. As the pH is varied, about 64% of the drug is released in acidic pH while 77% is released in neutral pH. The biocompatibility, efficiency of drug loading, and enhanced bioavailability of the capsule system was confirmed by MTT assay and in vivo biodistribution studies.
Keywords: drug delivery, layer-by-layer, electrostatic interaction, biocompatible
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.